FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors (FDA - Food and Drug Administration)

Edit Public Technologies 01 Jun 2016
This radioactive probe will help locate tumors in adult and pediatric patients with the rare condition, somatostatin receptor positive neuroendocrine tumors (NETs) ... 'Use of advanced imaging techniques to detect rare neuroendocrine tumors at an early stage in patients is critical,' said Libero Marzella, M.D., Ph.D., director of the Division of Medical Imaging Products in the FDA's Center for Drug Evaluation and Research....

FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors

Edit PR Newswire 01 Jun 2016
SILVER SPRING, Md., June 1, 2016 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging. This radioactive ... ....

Advanced Accelerator Applications Reports 29.6% Sales Growth in the First Quarter of 2016 – Strengthens Commercial Platform for Launch of Somakit and Lutathera (Advanced Accelerator Applications SA)

Edit Public Technologies 31 May 2016
Additional Lutathera NETTER-1 Phase III data were presented both on January 22, 2016 at the 2016 Gastrointestinal Cancer Symposium (ASCO GI) in San Francisco, California and on March 11, 2016 at the 13th Annual European Neuroendocrine Tumor Society (ENETS) conference in Barcelona, Spain ... kit for neuroendocrine tumor diagnosis and follow-up....

Strongbridge Biopharma plc Announces Presentation of COR-003 and COR-005 Data at the European Congress of Endocrinology (Strongbridge Biopharma plc)

Edit Public Technologies 31 May 2016
COR-005 is a next-generation somatostatin analog (SSA) with a unique receptor binding and activation profile to somatostatin receptor subtypes, being investigated for the treatment of acromegaly, with potential additional applications in Cushing's disease and neuroendocrine tumors ... applications in Cushing's syndrome and neuroendocrine tumors....

Lexicon Announces FDA Priority Review of New Drug Application for Telotristat Etiprate for the Treatment of Carcinoid Syndrome (Lexicon Pharmaceuticals Inc)

Edit Public Technologies 31 May 2016
(Source ... (Nasdaq ... Carcinoid syndrome is a rare disease affecting thousands of cancer patients with metastatic neuroendocrine tumors (mNETs) that have spread to the liver and other organs from the gastrointestinal tract ... While existing treatments for carcinoid syndrome work to reduce the release of serotonin outside tumor cells, telotristat etiprate works at the source to reduce serotonin production within the tumor cells ... market ... (noodl....

Mouse studies hold promise for a simple treatment for an aggressive gastric tumor

Edit Science Daily 20 May 2016
Patients with aggressive neuroendocrine tumors (NETs) have limited treatment options and there are few oncologists who are specialized in this relatively rare disease. Normally a total gastrectomy (removal of the stomach) is employed in these cases, with a subsequent dramatic reduction in the quality of life for patients ... ....

Sunitinib Malate Market worth 76.7 Million USD by 2021 (Markets and Markets Limited)

Edit Public Technologies 19 May 2016
A number of factors, such as increasing incidence of pancreatic cancer, availability of a limited number of drug therapeutic options for the treatment of advanced pancreatic neuroendocrine tumors, and poor diagnosis rate in the early stages of pancreatic cancer are driving the demand of sunitinib malate in the treatment of pancreatic cancer....

Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting (Novartis AG)

Edit Public Technologies 19 May 2016
... 4, 1.00 PM CDT] A Phase II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC) [Abstract #4074; Saturday, June 4, 8.00 AM CDT] Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin....

Camurus Interim Report January-March 2016

Edit Business Wire 17 May 2016
STOCKHOLM--(BUSINESS WIRE)--Regulatory News. Camurus AB (STO.CAMX). “We are in a strong growth phase and on track to deliver on all our key objectives for this year.” Business highlights first quarter 2016 Recruitment goals reached in two Phase 3 trials of CAM2038 for opioid dependence treatment ... Completion of Phase 2 study of CAM2029 in two patient groups with acromegaly or neuroendocrine tumors. Completion of Phase 1 study of CA ... ....

Strongbridge Biopharma plc Reports First Quarter 2016 Financial Results

Edit Stockhouse 17 May 2016
First Quarter 2016 Results ... initial public offering, which was completed in October 2015.  ... About Strongbridge Biopharma ... Strongbridge’s rare endocrine disease franchise also includes COR-005, a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors ... For more information, visit www.strongbridgebio.com ...  ....

Strongbridge Biopharma plc Reports First Quarter 2016 Financial Results (Strongbridge Biopharma plc)

Edit Public Technologies 17 May 2016
(Source. Strongbridge Biopharma plc) ... 'Strongbridge remains focused on accelerating development of its rare endocrine disease portfolio ... First Quarter 2016 Results ... Strongbridge's rare endocrine disease franchise also includes COR-005, a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors ... 2016 2015 ... 2016 2015....

Chiasma Reports First Quarter 2016 Results (Chiasma Inc)

Edit Public Technologies 11 May 2016
(Source. Chiasma Inc). WALTHAM, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc ... Marketing, G&A; Expenses ... Net Loss ... commercial launch of Mycapssa for adult patients with acromegaly, initiate a clinical trial of octreotide capsules supporting the potential treatment of patients with neuroendocrine tumors in late 2016, and advance its preclinical work to enable the company to announce a second product candidate by the end of 2016....

Better way to diagnose, manage neuroendocrine tumors

Edit Science Daily 10 May 2016
Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in the United States for detecting neuroendocrine tumors (NETS), and could significantly impact treatment management, a new study suggests ... ....
×